Molecular Staging

Molecular Staging is addressing this demand with a portfolio of products and services based on technologies that are transforming the detection and measurement of both proteins and nucleic acids.

  • New Haven, CT August 13, 2001– Molecular Staging Inc., today announced that, together with Amersham Pharmacia Bio-tech, the two companies have developed a simple method of using Rolling Circle Amplification to copy circular DNA for sequencing, 10,000 fold in a few hours.

    “This procedure, which removes the need for lengthy growth periods and traditional DNA isolation procedures, will deliver operational efficiency gains for DNA sequencing centers and genomics companies” said Dr. Stephen Kingsmore, COO of Molecular Staging Inc.

    The method is very simple, involving only a few steps, namely heat lysis of the organism containing the DNA of interest and an isothermal amplification step.
    Read the rest of this entry »

    Comments Off on Paper published in Genome Research describes a procedure for rapid amplification of circular DNA developed by Molecular Staging Inc. and Amersham Pharmacia Biotech
  • New Haven, CT. June 4, 2001 – Molecular Staging Inc. (MSI) today confirmed that Motorola will not exercise an option to license Rolling Circle Amplification technology (RCAT™) for applications in the clinical diagnostics market. Instead, Motorola Inc. intends to pursue the use of RCAT™ for a number of research applications.

    Motorola Inc. and MSI entered into a license option agreement related to the use of RCAT™ on clinical diagnostic microarrays, November 7, 2000, whereby Motorola Inc. paid certain research • fees and made an equity investment in MSI. The agreement provided for an evaluation period during which Motorola Inc and MSI would work together to meet specific technical milestones.
    Read the rest of this entry »

    Comments Off on Molecular Staging Inc updates Motorola Inc.’s intended usage of Rolling Circle Amplification Technology.
  • Funding will enhance Molecular Staging’s leadership position in signal and target amplification and accelerate MSI’s efforts in the proteomics, genomics and molecular diagnostics markets.

    NEW HAVEN, CT — Molecular Staging Inc. (MSI), a privately-held life sciences tool company, announced today that it has completed a Series D preferred stock financing totaling $41.25 million. Investor AB, through Investor Growth Capital, participated in the private placement along with OrbiMed, CIBC Capital Partners and Cooper Hill Partners. Domain Partners III, CHL Medical Partners and 3i Bioscience Investment Trust, who were already holders of preferred stock in Molecular Staging, also participated in the new round of financing. Investor AB and OrbiMed will be entitled to name two representatives to the board.

    Liza Page Nelson, Managing Director of Investor Growth Capital said “Molecular Staging has made tremendous progress in the development and validation of its key platforms. Seldom does one find a company whose technology can broadly address so many markets; these include research reagents, drug research and development, diagnostics, and life sciences.”
    Read the rest of this entry »

    Comments Off on Molecular Staging Completes $41.25 Million Private Financing
  • Ultra-sensitive Prototype Assay for Prostate Cancer Marker Also Reported
    PRINCETON, N.J., Oct. 2 /PRNewswire/ — AxCell Biosciences Corporation, a subsidiary of Cytogen Corporation (Nasdaq: CYTO – news) and Molecular Staging, Inc., (MSI), Guilford, CT, initiated a scientific plan to investigate potential synergies between their technologies to map protein pathways more rapidly and efficiently. MSI’s Rolling Circle Amplification Technology (RCATTM) is a proprietary, highly sensitive and efficient amplification method for detecting the presence of target molecules micro-arrayed on a biochip. By combining AxCell’s domain-ligand interaction technology with MSI’s protein arrays, the two companies believe that they may be able to increase the rate of protein interaction measurements by 10 fold more than AxCell’s current rate of approximately 10,000 interactions per day.
    Read the rest of this entry »

    Comments Off on Cytogen’s AxCell Biosciences and Molecular Staging to Investigate Biochips to Accelerate Mapping of Human Proteome
  • PRINCETON, N.J., Sept. 28 /PRNewswire/ — Cytogen Corporation (Nasdaq: CYTO) announced today that it had signed a letter of intent to obtain an exclusive, worldwide license from Molecular Staging, Inc. (MSI) of Guilford, CT, for their novel Rolling Circle Amplification Technology (RCAT) to develop in vitro diagnostic tests for Prostate Specific Membrane Antigen (PSMA) and Prostate-Specific Antigen (PSA).

    Serum PSA testing has revolutionized the diagnosis and management of prostate cancer and several million tests are done every year in the United States to screen for malignancy. It is estimated that over $400 million is now spent on PSA testing. However, in two-thirds of men with an elevated PSA the cause is something other than cancer, so the patient is caused needless anxiety and subjected to unnecessary investigation.
    Read the rest of this entry »

    Comments Off on Cytogen Corporation to Acquire Novel Diagnostic Technology from Molecular Staging, Inc. to Develop Improved Prostate Cancer Tests
  • NEW HAVEN, April 18, 2002/– Molecular Staging Inc. (MSI) today announced the publication of a landmark paper in this month’s issue of Nature Biotechnology that describes a new approach to analyzing multiple proteins simultaneously on a glass chip microarray.

    The paper, entitled “Multiplexed Protein Profiling on Microarrays using Rolling Circle Amplification (RCAT),” describes a chip based proteomics discovery platform that employs RCAT to amplify signals from proteins in a highly multiplexed format.
    Read the rest of this entry »

    Comments Off on Multiplexed Protein Profiling on Protein Chips Using Rolling Circle Amplification
  • NEW
    HAVEN, April 16, 2002/– Molecular Staging Inc.
    (MSI) today announced the publication of a paper in
    today’s issue of Proceedings of the National Academy of
    Sciences of the United States of America (PNAS) that
    describes a method for generating millions of DNA copies
    from just a few cells.
    Read the rest of this entry »

    Comments Off on New Technology Increases the Availability of
  • NEW HAVEN, April 4, 2002/– Molecular Staging Inc. (MSI) today announced that it has been awarded three additional patents for Rolling Circle Amplification Technology (RCATTM). MSI now has a total of fourteen issued patents in the U.S., Europe and Australia covering this technology and its applications.
    Read the rest of this entry »

    Comments Off on Molecular Staging Inc. Awarded Three Additional Patents for Rolling Circle Amplification Technology
  • NEW HAVEN, CT, December 11, 2001 – Molecular Staging Inc. (“MSI”) today announced publication of a paper in the November issue of Nucleic Acids Research that describes the application of the Company’s proprietary Rolling Circle Amplification Technology (RCATTM) to detect nucleic acids on microarrays.
    Read the rest of this entry »

    Comments Off on Study Demonstrates Increased Sensitivity Of Rolling Circle Amplification TechnologyTM In Detecting Nucleic Acids On Microarrays
  • NEW HAVEN, CT., October 30, 2001/– Molecular Staging Inc. (MSI) today announced a published abstract in the October 2001 issue of Clinical Chemistry. The abstract described the application its of MSI’s Rolling Circle Amplification TechnologyTM (RCATTM) for the detection of allergen-specific IgE, the antibody in patient serum used to predict an allergic response in individuals with concordant clinical history.
    Read the rest of this entry »

    Comments Off on Circle AmplificationTM in Detecting Allergen-specific IgE on Microarrays Published